Centella asiaticahas been recognized for centuries in Eastern medicine for its pharmacological properties. Due to the increasing prevalence of oncological diseases worldwide, natural substances that could qualify as anticancer therapeutics are becoming increasingly important subjects of research. This review aims to find an innovative use for asiatic acid (AA) in the treatment or support of cancer therapy. It has been demonstrated that AA takes part in inhibiting phosphorylation, inducing cell death, and reducing tumor growth and metastasis by influencing important signaling pathways, such as PI3K, Akt, mTOR, p70S6K, and STAT3, in cancer cells. It is also worth mentioning the high importance of asiatic acid in reducing the expression of markers such as N-cadherin, β-catenin, claudin-1, and vimentin. Some studies have indicated the potential of asiatic acid to induce autophagy in cancer cells through changes in the levels of specific proteins such as LC3 and p62. It can also act as an anti-tumor immunotherapeutic agent, thanks to its inductive effect on Smad7 in combination with naringenin (an Smad3 inhibitor). It seems that asiatic acid may be a potential anticancer drug or form of adjunctive therapy. Further studies should take into account safety and toxicity issues, as well as limitations related to the pharmacokinetics of AA and its low oral bioavailability.
积雪草因其药理特性在东方医学中已被认知数世纪。随着全球肿瘤性疾病患病率不断上升，具备抗癌治疗潜力的天然物质日益成为重要的研究对象。本综述旨在探索积雪草酸在癌症治疗或辅助治疗中的创新应用。研究表明，积雪草酸通过影响PI3K、Akt、mTOR、p70S6K和STAT3等重要信号通路，参与抑制磷酸化、诱导细胞死亡、减少肿瘤生长和转移的过程。特别值得关注的是，积雪草酸在降低N-钙黏蛋白、β-连环蛋白、闭合蛋白-1及波形蛋白等标志物表达方面具有显著作用。部分研究指出，积雪草酸可能通过改变LC3和p62等特定蛋白水平，诱导癌细胞自噬。与柚皮素（Smad3抑制剂）联用时，其通过诱导Smad7表达还可发挥抗肿瘤免疫治疗作用。积雪草酸有望成为潜在的抗癌药物或辅助治疗手段。后续研究需重点关注其安全性与毒性问题，并克服积雪草酸药代动力学特性及口服生物利用度低等局限性。
Can Asiatic Acid fromCentella asiaticaBe a Potential Remedy in Cancer Therapy?—A Review
肿瘤(癌症)患者之家